We are developing regulatory pathways that are appropriate for point-of-care manufacturing. This is in response to stakeholder feedback received during the introduction of the personalised medical devices framework.
To ensure regulation for medical devices manufactured at the point-of-care remains fit-for-purpose, the TGA has developed four surveys, each targeted at major stakeholder groups, to collect information on the potential impact of the current regulatory environment. The four surveys are:
- Dental and oral health survey: for professionals, practitioners and technicians involved in the dental sector
- Allied health professionals survey: for all practitioners and professionals in the allied health sector including orthotists, prosthetists, podiatrists and occupational therapists/rehabilitation therapists
- Medical device manufacturing hubs at the POC survey: for manufacturing hubs located in hospitals, clinics and other facilities where medical devices are manufactured including academic and research-based facilities
- Hospital and healthcare facility survey: for policy and governance teams located in hospitals and healthcare facilities where medical devices are manufactured either in hubs or by professionals and practitioners
The surveys will remain open for six weeks from Saturday 25 March until Sunday 7 May 2023.
Information collected via these surveys will NOT be used to conduct compliance activities.
A new framework has been introduced to ensure an appropriate level of regulation is applied to Personalised Medical Devices to manage the risk these devices may pose.
Prior to 25 February 2021, most personalised medical devices (PMD) met the definition of 'custom-made' and were exempt from the requirement to be approved by the TGA and included in the Australian Register of Therapeutic Goods (ARTG) before they could be imported, exported or supplied (though they were subject to other regulatory obligations).
Over the past two decades, rapid advances in computing technology and materials science have resulted in significant changes to medical imaging technology, manufacturing technology and, as a result, medical device technology. Newer methods of manufacture such as 3D-printing allowed more complex and, in some cases, higher-risk medical devices to be personalised for an individual patient and supplied under the custom-made medical device exemption.
Following extensive consultation and liaison with other global regulators, the Therapeutic Goods Administration (TGA) developed a new regulatory framework for PMD. This new framework has been introduced by the Government to ensure an appropriate level of regulation is applied to PMD in order to manage the risk they may pose. The new framework came into effect on 25 February 2021, and includes:
- new definitions for personalised medical devices, including patient-matched and adaptable medical devices, that reduce the scope of the custom-made medical device exemption
- changes to the conditions of exemption for custom-made medical devices
- new requirements for the inclusion of Medical Device Production System (MDPS) in the ARTG.
Medical Device Production Systems (MDPS)
MDPS are a new concept in medical device regulation where an end-to-end system for the manufacture of medical devices can be included in the ARTG, thereby allowing medical devices to be manufactured within healthcare facilities without the need for the facility to include those devices in the ARTG. While the definition of an MDPS is included in the Therapeutic Goods (Medical Devices) Regulations 2002, this definition will not take effect until a subsequent legislative instrument declaring an MDPS to be a medical device is in place. This subsequent legislative instrument is likely to be drafted following work currently underway with the International Medical Device Regulators Forum (IMDRF) and once the TGA has established regulatory structures to appropriately assess and evaluate these systems. This work is progressing.
Patient-matched medical devices
The deadline to register patient-matched medical devices for transition to inclusion in the ARTG closed on 25 August 2022. Patient-matched medical devices that have not been registered for transition must be included in the Australian Register of Therapeutic Goods (ARTG) prior to import or supply (unless exempt or excluded).
An exemption has been introduced allowing the supply of up to five (5) of a kind of patient-matched medical device to be supplied in a financial year without requiring an ARTG inclusion.
Guidance for industry
A guidance document for the new regulatory framework for PMD is available at: Personalised medical devices (including 3D-printed devices).
For answers to frequently asked questions about the framework, see Regulatory framework for personalised medical devices: Frequently asked questions.
An overview of Refinements to the Personalised Medical Devices Framework made in August 2021.
For information about advertising personalised medical devices to consumers, see General requirements for advertising personalised medical devices to consumers.
|Proposed regulatory changes related to personalised and 3D printed medical devices||Consultation closed 22 December 2017|
|Proposed regulatory scheme for personalised medical devices, including 3D-printed devices||Consultation closed 31 March 2019|
|Proposed refinements to the regulation of personalised medical devices||Consultation closed 14 July 2021|
For more information see Consultations and reviews.
Dental Sector Working Group
On 9 April 2021, the TGA held a workshop with key representatives of the Australian dental sector to discuss the implementation of the new regulatory framework for personalised medical devices in the specifically in the dental sector.
Following on from this workshop a working group of volunteers has been established to continue to work closely with the TGA, providing input, advice and feedback on the implementation and concerns raised by the sector.
For more information see Personalised medical devices: Dental Sector Working Group.
Keep up to date
Please contact the TGA at firstname.lastname@example.org should you have any queries or comments.
You can also send an email to email@example.com with 'SUBSCRIBE PMD' in the subject line to receive:
- notification when guidance documents and other information resources are published
- updates about the new framework
- details about webinars and workshops
Follow us on social media.
For more information about other reforms visit Medical devices reforms.